Quote:

---

A typical licensing royalty would be tiered and a the royalty range would be from the high single digits in percentage to the lower teens, with a higher or lower range depending on the stage the drug is in.

---

The deal you're talking about here is for the licensing company to "own" the drug and take over all aspects of trials, production and distribution. The Vyera deal was only for distribution, thus the higher percentage. Any larger company would have insisted on distribution for all indications at a likely more disadvantaged split for Cytodyn. With the myriad of indications a distribution for all would not be the best result for Cytodyn in the long run.